louisakewell, Author at European Medical Journal - Page 122 of 153

Continue
EMJ
24th April 2015

Targeting BCL-2 for treating oestrogen-positive breast cancer

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Geoff Lindeman (The Walter and Eliza Hall Institute of Medical Research, Victoria…
EMJ
24th April 2015

Highlights from the St. Gallen Breast Cancer Conference 2015

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Giuseppe Viale (European Institute of Oncology and University of Milan, Milan…
EMJ
24th April 2015

The current biosimilar landscape

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Paul Declerck (KU Leuven, Leuven, Belgium) discusses the understanding of the…
EMJ
24th April 2015

Biosimilars for breast cancer treatment

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Peter Schmid (Barts Cancer Institute, London, UK) discusses the key challenges…
EMJ
24th April 2015

CDK 4/6 inhibitor, palbociclib, for the treatment of metastatic breast cancer

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Richard Finn (UCLA, Los Angeles, CA) discusses the development of the cyclin…
EMJ
24th April 2015

Ki67 as a marker for making management decisions in breast cancer

At the 14th St. Gallen International Breast Cancer Conference 2015, Dr John Bartlett (Ontario Institute for Cancer Research, Toronto, Canada) discusses…
EMJ
24th April 2015

New drugs in neoadjuvant breast cancer therapy

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof Sibylle Loibl (German Breast Group, Neu-Isenburg, Germany) discusses recent…
EMJ
24th April 2015

Are randomised trials obsolete or more important than ever?

At the 14th St. Gallen International Breast Cancer Conference (SG-BCC) 2015, Dr Clifford Hudis (Memorial Sloan Kettering Cancer Center, New York, NY) Dr…
EMJ
1 Mins
20th April 2015

Saunas Take the Heat Off Heart Disease

MEN who regularly use a sauna have a significantly lower risk of cardiovascular (CV) and all-cause mortality than those who attend less frequently.
EMJ
1 Mins
20th April 2015

Fondaparinux the Best Option to Tackle NSTEMI?

DEATH and in-hospital bleeding in patients with non-ST-segment elevation myocardial infarction (NSTEMI) appears less likely through the use of…